Recurrence Prevention and Strengthening of Company-Wide Controls Based on Special Investigation Committee Recommendations
First written in FY2022-Q2. 6 of 8 entries say "Restated". Latest entry: FY2024-Q3.
The whole theme swung hardest in 2022: 1 of 10 companies on the "Worse" side.
8 other companies' latest entry also says "Restated".
- FY2024-Q3RestatedAnnual report
「The company recognizes the importance of internal control over financial reporting. To rectify these material deficiencies requiring disclosure, and taking into account the findings and recommendations of the special investigation committee, it submitted an Improvement Report to the Tokyo Stock Exchange on 31 January 2022, formulated the following measures to prevent recurrence, and is working to establish and operate appropriate internal controls.」
The company has reaffirmed its explanation that it is proceeding with the submission of an Improvement Report, the formulation of 10 measures to prevent recurrence, and the establishment and operation of appropriate internal controls. No new completion milestone has been indicated. - FY2024-Q2RestatedAnnual report
「The company recognizes the importance of internal control over financial reporting. To rectify these material deficiencies requiring disclosure, and taking into account the findings and recommendations of the special investigation committee, it submitted an Improvement Report to the Tokyo Stock Exchange on 31 January 2022, formulated the following measures to prevent recurrence, and is working to establish and operate appropriate internal controls.」
The company has reaffirmed its explanation that it is proceeding with the submission of an Improvement Report, the formulation of 10 measures to prevent recurrence, and the establishment and operation of appropriate internal controls. No new completion milestone has been indicated. - FY2024-Q1RestatedAnnual report
「The company recognizes the importance of internal control over financial reporting. To rectify these material deficiencies requiring disclosure, and taking into account the findings and recommendations of the special investigation committee, it submitted an Improvement Report to the Tokyo Stock Exchange on 31 January 2022, formulated the following measures to prevent recurrence, and is working to establish and operate appropriate internal controls.」
The company has reaffirmed its explanation that it is proceeding with the submission of an Improvement Report, the formulation of 10 measures to prevent recurrence, and the establishment and operation of appropriate internal controls. No new completion milestone has been indicated. - FY2023-Q3RestatedAnnual report
「The company recognizes the importance of internal control over financial reporting. To rectify these material deficiencies requiring disclosure, and taking into account the findings and recommendations of the special investigation committee, it submitted an Improvement Report to the Tokyo Stock Exchange on 31 January 2022, formulated the following measures to prevent recurrence, and is working to establish and operate appropriate internal controls.」
The company has reaffirmed its explanation that it is proceeding with the submission of an Improvement Report, the formulation of 10 measures to prevent recurrence, and the establishment and operation of appropriate internal controls. No new completion milestone has been indicated. - FY2023-Q2RestatedAnnual report
「The company recognizes the importance of internal control over financial reporting. To rectify these material deficiencies requiring disclosure, and taking into account the findings and recommendations of the special investigation committee, it submitted an Improvement Report to the Tokyo Stock Exchange on 31 January 2022, formulated the following measures to prevent recurrence, and is working to establish and operate appropriate internal controls.」
The company has reaffirmed its explanation that it is proceeding with the submission of an Improvement Report, the formulation of measures to prevent recurrence, and the establishment and operation of appropriate internal controls. The same 10 measures as in the previous disclosure are described, with no new completion milestone indicated. - FY2023-Q1AdvancedAnnual report
「The company submitted an Improvement Report to the Tokyo Stock Exchange on 31 January 2022, formulated the following measures to prevent recurrence and is working to establish and operate appropriate internal controls.」
After submitting an Improvement Report, the company formulated and implemented 10 measures to prevent recurrence, including promoting understanding of accounting standards, establishing and monitoring internal accounting standards, strengthening administrative functions, improving communication between auditors and management, organizing contractual and rights-related matters, managing development projects, internal audits and an internal whistleblowing system. - FY2022-Q3RestatedAnnual report
「Taking into account the recommendations of the special investigation committee, the company plans to formulate and disclose measures to prevent recurrence. Going forward, it will steadily implement these measures, sincerely work to further strengthen the establishment and operation of appropriate internal controls, and work to prevent recurrence.」
The company has reaffirmed its policy of formulating and disclosing measures to prevent recurrence based on the special investigation committee's recommendations and strengthening the establishment and operation of internal controls. Completion of the measures was not disclosed. - FY2022-Q2First statedAnnual report
「Taking into account the recommendations of the special investigation committee, the company plans to formulate measures to prevent recurrence. Going forward, it will steadily implement these measures, recognize the importance of internal controls, further advance projects to review its regulations and rules and strengthen company-wide controls, establish and operate internal controls thoroughly, and work to prevent recurrence by building an organization focused on company-wide controls.」
Following the accounting errors in prior fiscal years and the overstatement of software-related assets, the company provided its first specific indication of a policy to advance measures to prevent recurrence based on the special investigation committee's recommendations, review its regulations and rules, and strengthen company-wide controls. Completion of the measures was not disclosed.